Retrospective Analysis Of Clinical Cases Of Qili Qiangxin Capsule In The Treatment Of Heart Failure With Improved Ejection Fractio

Purpose:To evaluate the clinical efficacy of Qiliqiangxin capsule on treatment of ejection fraction improved heart failure(Xinyang deficiency,collateral-stasis and water withdrawal syndrome)through clinical retrospective study,to further verify the efficacy and safety of Qiliqiangxin capsule,to summarize clinical experience and explore its mechanism of action.Material and method:In this study,patients treated in the second Department of Cardiology at the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from August 2019 to September 2022 were screened.According to inclusion criteria and exclusion criteria,60 patients with complete medical records diagnosed as ejection fraction improved heart failure in Western medicine and hydrocardiopathy in traditional Chinese medicine were selected as research objects.The above patients were divided into traditional Chinese medicine group(Qiliqiangxin capsule + basic Western medicine)and basic treatment group(basic Western medicine),30 cases in each group,treatment time ≥4 weeks later,Traditional Chinese medicine symptoms,tongue and pulse,NYHA cardiac function grade,left ventricular ejection fraction(LVEF)and N-terminal B-type natriuretic peptide(NT-proBNP)data of patients before and after treatment were collected and sorted,and SPSS was applied 26.0 Software analysis system analyzed the changes of traditional Chinese medicine syndrome score,NYHA cardiac function level,EF value and NT-proBNP level,etc.To analyze the efficacy of Qiliqiangxin capsule and summarize its mechanism of action.Results:1.The curative effect of TCM symptoms: chest tightness,shortness of breath,fatigue,limb edema,cold limbs,palpitation,cough,less urine,tongue and pulse after treatment in both groups had statistical significance(p < 0.01),and the curative effect of traditional Chinese medicine treatment group was significantly better than the basic treatment group(p < 0.01).In the treatment group,13 cases(43.3%)were markedly effective,15 cases(50%)were effective,and the total effective rate was 93.3%,while in the basic treatment group,4 cases(13.3%)were markedly effective,21 cases(70%)were effective,and the total effective rate was 83.3%.2.The improvement of NYHA cardiac function: 17 cases(56.7%),11 cases(36.7%),and the total effective rate was 93.3% in the treatment group,10 cases(33.3%),12 cases(40%)in the basic treatment group,the total effective rate was 73.3%.The curative effect of TCM Group was better than that of basic treatment group(p < 0.05).3.The change of LVEF was 44.10% ± 2.20% before treatment and 49.50% ± 3.15% after treatment in traditional Chinese medicine group and 43.70% ± 2.23% before treatment in basic treatment group,the mean value of LVEF after treatment was 46.20% ± 2.08%.The results showed that the effect of TCM treatment group was better than that of basic treatment group in improving ejection fraction(p < 0.01).4.NT-proBNP level: the mean value of NT-proBNP before treatment was(3930.48±987.50) pg/ml,and the mean value of NT-proBNP after treatment was(1340.92±774.54)pg/ml;The mean value of NT-proBNP before treatment was(3853.45±907.80)pg/ml,and the mean value of NT-proBNP after treatment was(2034.90±950.30)pg/ml.It can be seen that the curative effect of TCM treatment group is better than that of basic treatment group(p<0.05).Conclusion:1.Qiliqiangxin capsule combined with routine western medicine can obviously improve the clinical symptoms,cardiac function,left ventricular ejection fraction and NT-proBNP level of the patients with heart failure with improved ejection fraction.2.Qiliqiangxin Capsule has good efficacy and safety for treatment of ejection fraction improved heart failure(Xinyang deficiency syndrome,collateral-stasis and water-stopping syndrome),providing effective clinical regimen for the treatment of this disease.